You are here
My lab is developing therapies for cancer and neurofibromatosis based on the Ras pathway. We are attempting to develop drugs that target KRAS directly, and we are using siRNA in vitro and in vivo to target KRAS and its downstream effectors. We have evidence that KRAS activates stem-like phenotype that accounts for its potency as an oncogene in cancer. RAS proteins are regulated by GAPs and by Sprouty proteins. We have discovered that SPROUTY-like proteins serve as adapters to direct specific GAPs to cell growth factor receptors and are investigating new aspects of special organization of RAS and related proteins.